Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Zealand Pharma Announces Results From Phase 3 Trial Of Glepaglutide; Glepaglutide Treatment Met Primary Endpoint

Author: Benzinga Newsdesk | September 30, 2022 05:17am

Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)

Glepaglutide treatment met the primary endpoint with twice weekly dosing achieving a statistically significant reduction in weekly parenteral support volume by 5.13 Liters/week from baseline at 24 weeks
66% of patients in the twice weekly group had a clinically meaningful response (>20% reduction in parenteral support volume)
In total 9 patients treated with glepaglutide were weaned off parenteral support, while no placebo treated patients were able to wean off parenteral support
Glepaglutide treatment was assessed as safe and was well-tolerated in the trial
Conference call scheduled today at 8:00 a.m. ET / 2:00 p.m. CET

Posted In: ZEAL